Managed care aspects of managing multiple sclerosis

American Journal of Managed Care

Volumn 19, Issue 2 SUPPL, 2013, Pages

  Mathis, A Scott ^a  

^a MONMOUTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PATHWAY; CLINICAL TRIAL (TOPIC); COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DISPARITY; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; MANAGED CARE; MANAGED CARE ORGANIZATION; MEDICATION COMPLIANCE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT DECISION MAKING; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE MANAGEMENT; ECONOMICS; HEALTH CARE DELIVERY; PHARMACY; QUALITY ADJUSTED LIFE YEAR; SPECIALIZATION; ARTICLE;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; CRITICAL PATHWAYS; DISEASE MANAGEMENT; HEALTH SERVICES ACCESSIBILITY; HUMANS; MANAGED CARE PROGRAMS; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS; PHARMACEUTICAL SERVICES; QUALITY-ADJUSTED LIFE YEARS; SPECIALIZATION;

EID: 84891716290     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17(suppl 5):S139-S145.
2. Berger JR. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies. Am J Manag Care. 2011;17(suppl 5):S146-S153.
3. Tam S, Lopez A, Shek A, Yeh J. Multiple sclerosis: a paradigm change with oral agents? Formulary. 2011;46:228-240.
4. Forbes A, While A, Mathes L, Griffiths P. Health problems and health-related quality of life in people with multiple sclerosis. Clin Rehabil. 2006;20(1):67-78. (Pubitemid 43246334)
5. Ivanova JI, Birnbaum HG, Samuels S, et al. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmacoeconomics. 2009;27(8):681-691.
6. Patwardhan MB, Matchar DB, Samsa GP, et al. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler. 2005;11(2):232-239. (Pubitemid 40403265)
7. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health. 2004;7(5):554-568. (Pubitemid 39390836)
8. Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R. Costeffectiveness analysis of disease modifying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients. J Med Econ. 2012;15(3):424-433.
9. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13(3):245-261. (Pubitemid 46730893)
10. Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2009;15(7):543-555.
11. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
12. Zintaras E, Doxani C, Mprotsis T, et al. Network analysis of randomized controlled trials in multiple sclerosis. Clin Ther. 2012;34(4):857-869.
13. Lee S, Baxter DC, Limone B, et al. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. J Med Econ. 2012;15(6):1088-1096.
14. Heisen M, Treur MJ, van der Hel WS, et al. Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands. J Med Econ. 2012;15(6):1149-1158.
15. O'Day K, Meyer K, Miller RM, et al. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ. 2011;14(5):617-627.
16. Chiao E, Meyer K. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. Curr Med Res Opin. 2009;25(6):1445-1454.
17. Gleason PP, Starner CI, Gunderson BW, et al. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009;15(8):648-658.
18. Margolis JM, Fowler R, Johnson BH, et al. Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. BMC Neurol. 2011;11:122.
19. Lundkvist J, Kastäng F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ. 2008;8(suppl 2):S49-S60.
20. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28(1):51-61.
21. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527-539.
22. National Clinical Advisory Board of the National Multiple Sclerosis Society. Disease management consensus statement. New York, NY: National Multiple Sclerosis Society; 2008.
23. Miller RM, Happe LE, Meyer KL, Spear RJ. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians. J Manag Care Pharm. 2012;18(1): 54-62.
24. Sperandeo K, Nogrady L, Moreo K, Prostko CR. Managed approaches to multiple sclerosis in special populations. J Manag Care Pharm. 2011;17(9, suppl C):S1-S19.
25. Setting new standards in multiple sclerosis care and research. Lancet Neurol. 2012;11(10):835.
26. Freedman MS. Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology. 2011;76(1, suppl 1):S26-S34.
27. Curkendall SM, Wang C, Johnson BH, et al. Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy. Clin Ther. 2011;33(7):914-925.
28. Nicholas R, Straube S, Schmidli H, et al. Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis. Mult Scler. 2012;18(9):1290-1296.
29. Schwartz CE, Bode RK, Quaranto BR, Vollmer T. The symptom inventory disability-specific short forms for multiple sclerosis: construct validity, responsiveness, and interpretation. Arch Phys Med Rehabil. 2012;93(9):1617-1628.
30. Stockl KM, Shin JS, Gong S, et al. Improving patient self-management of multiple sclerosis through a disease therapy management program. Am J Manag Care. 2010;16(2):139-144.
31. Motl RW, Gosney JL. Effect of exercise training on quality of life in multiple sclerosis: a meta-analysis. Mult Scler. 2008;14(1):129-135. (Pubitemid 351541406)
32. Akkus Y, Akdemir N. Improving the quality of life for multiple sclerosis patients using the nurse-based home visiting model. Scand J Caring Sci. 2012;26(2):295-303.
33. Winters S, Jackson P, Sims K, Magilvy J. A nurse-managed multiple sclerosis clinic: improved quality of life for persons with MS. Rehabil Nurs. 1989;14(1):13-22.
34. Finlayson M, Preissner K, Cho C, Plow M. Randomized trial of a teleconference-delivered fatigue management program for people with multiple sclerosis. Mult Scler. 2011;17(9):1130-1140.
35. Miller DM, Moore SM, Fox RJ, et al. Web-based self-management for patients with multiple sclerosis: a practical, randomized trial. Telemed J E Health. 2011;17(1):5-13.
36. Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease modifying therapy for multiple sclerosis: a population-based study. Neurology. 2011;77(4):355-363.